Research programme: non-small cell lung cancer therapeutics - Benitec

Drug Profile

Research programme: non-small cell lung cancer therapeutics - Benitec

Alternative Names: Tribetarna

Latest Information Update: 11 Jan 2015

Price : $50

At a glance

  • Originator Childrens Cancer Institute Australia for Medical Research
  • Developer Benitec Biopharma
  • Class Small interfering RNA
  • Mechanism of Action Beta III tubulin protein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Non-small cell lung cancer

Most Recent Events

  • 11 Jan 2015 Research programme: non-small cell lung cancer therapeutics - Benitec is available for licensing as of 11 Jan 2015. http://www.benitec.com
  • 08 Jan 2015 Pharmacodynamics data from a preclinical study in Pancreatic cell cancer released by Benitec Biopharma
  • 03 Jun 2013 Preclinical development is ongoing in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top